Table 2. Eicosanoid levels in tumor-bearing lungs of WT and cPLA2-KO mice.

	WT	WT	WT	cPLA2-KO	cPLA2-KO	cPLA2-KO
analyte	No tumor	Tumor 2wks	Tumor 3wks	No tumor	Tumor 2wks	Tumor 3 wks	% reduction KO vs WT in 3 wk tumors	FDR (adj. p-value)
DHA	1.5	1.6	4.1	1.1	1.2	3.1	24	0.185
	(1.3–1.9)	(1.3–2.1)	(3.5–6.0)	(1.0–1.4)	(1.1–1.5)	(2.4–4.7)
AA	8	10	63	6	8	47	25	0.172
	(8–10)	(9–11)	(50–66)	(5–7)	(7–9)	(38–58)
PGF2a	6	24	25	1	21	15	41	0.094
	(4–10)	(12–72)	(16–29)	(0–11)	(16–31)	(6–21)
12HETE	102	136	384	45	111	210	45	0.072
	(56–263)	(112–279)	(333–540)	(37–117)	(76–191)	(138–354)
15HETE	40	67	143	18	52	60	58	0.139
	(24–60)	(56–123)	(108–155)	(11–49)	(32–79)	(35–156)
5HETE	6	9	18	4	3	7	61	0.355
	(4–23)	(9–12)	(9–60)	(2–5)	(3–7)	(4–30)
PGD2	4	9	47	2	11	18	63	0.185
	(4–5)	(6–10)	(25–59)	(2–3)	(6–14)	(10–42)
PGE2	35	232	1587	25	176	575	64	0.182
	(26–45)	(104–300)	(574–1634)	(11–41)	(99–275)	(279–1382)
LTE4	4	19	43	4	0	10	76	0.031*
	(3–4)	(10–32)	(19–99)	(0–6)	(0–4)	(7–15)
TXB2	4	10	38	0	5	8	78	0.015*
	(3–12)	(7–17)	(22–43)	(0–3)	(3–6)	(5–15)
LTD4	3	1	5	3	2	1	79	0.012*
	(0–16)	(1–2)	(4–15)	(0–4)	(1–2)	(0–3)
6kPGF1a	82	107	57	11	49	12	79	0.015*
	(30–119)	(67–131)	(36–85)	(5–25)	(22–96)	(6–21)
LTC4	2	6	26	0	0	2	94	0.007*
	(0–36)	(0–8)	(14–39)	(0–1)	(0–0)	(0–5)
LTB4	0	0	0.36	0	0	0	100	0.075
	(0–0)	(0–0)	(0–0.68)	(0–0)	(0–0)	(0–0)

LLC-Luc cells or matrigel (control) were injected into left lung lobes of wild-type or cPLA₂-KO mice. Left lobes with tumor were harvested 2 or 3 weeks after injection, eicosanoids were analyzed by LC/MS/MS and normalized to protein content of the sample. Top numbers indicate median levels of each eicosanoid. Numbers in parentheses indicate the interquartile ranges. Eicosanoid levels are expressed as pg/mg protein, except for DHA and AA, which are measured in ng/mg protein. *FDR value <0.05